Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Siolta Therapeutics, an emerging biotech company in San Francisco, has developed a systems approach to live biotherapeutic product (LBP) development for the prevention and treatment of inflammatory diseases. Their proprietary platform provides 1) patient stratification, 2) immunomodulatory assessment, and 3) rationally engineered microbial therapeutics for targeted treatments. Siolta’s current focus is on the clinical development of its lead product to prevent and treat allergic asthma.
Appreciation for the role of microbes in our lives has been growing rapidly, but the measurement science needed to understand and fully exploit microbial systems has developed at a much slower pace than the industries dependent on them demand. NIST is developing standards for microbiome measurements that will enable federal, academic, and industry labs to reliably reproduce and advance each other's results. Microbiome standards will support research investigations and commercial translation of microbiome science by providing measurement assurance tools: standardized protocols, reference materials, validated measurements and critically evaluated reference data
Next Generation Sequencing (NGS) has become an integral part of the therapeutic product development process. It is especially important in live bio-therapeutic product development, specifically for performing quality control, characterizing the safety of microbial strains, informing patient selection for clinical trials, monitoring changes in the microbiome, and enabling downstream discovery.
However, there are challenges associated with incorporating NGS data in the development of microbiome therapeutics:
In this presentation, we will discuss how a leading pharmaceutical company uses the DNAnexus Platform to address these issues. We will also present our work to crowdsource the improvement of NGS-based methods through community challenges on the Mosaic Microbiome Platform.
When the gut microbiome (gBiome) is in an unhealthy state, an individual is in dysbiosis, which may be related to their diet and its nutritional value. The role of nutrition and the gBiome in health and disease has rapidly grown with the understanding of each, their interactions, and the links to gastrointestinal disease, obesity, and chronic disease. In the last decade, the availability of affordable next generation sequencing and gnotobiotics (germ-free animal models) has facilitated a major advancement in our understanding of the gBiome and the interaction with nutrition.
The relation between the gut microbiome and our neurological health has become very clear in recent years. Axial is developing new drug candidates to affect the microbiome and its metabolites, for potential treatments of neurological diseases, starting with Parkinson’s and autism spectrum disorder (ASD). We will discuss our ASD and Parkinson’s pipeline, as it approaches the clinic.
Gut microbiome plays a crucial role in the building-up of our immunity system at birth. It is a life-long personal and natural protection but increasing evidence suggests that dysregulated immune responses against commensal microbes in the gut are strongly involved in Inflammatory Bowel Diseases, Oncology, Metabolic disorders, Depression, Allergies amongst numerous diseases.
Our target and drug discovery platform is based on full sequencing and mapping of total fecal bacterial gene content that leads to the characterization of the gut metagenome associated with a disease phenotype. This technology enables the identification of genes and pathways of interest associated with the development of diseases.
The metagenomics dataset generated is then associated with a high throughput screening platform that allows the discovery of news drugs and targets. Two lead programs were discovered through this platform: EB8018 is an oral and non-systemic small molecule drug candidate that is designed to block FimH, a key virulence factor expressed by pro-inflammatory Enterobacteria. EB8018 prevents colonization of gut wall, mucosal inflammatory cytokine production and entry of such bacteria into the gut wall. E0510 : this program aims to discover novel bacterial-derived cancer antigens that are expressed in human gut microbiome. The first preclinical candidate (E02401) has demonstrated strong potency to induce T-cell activation against solid tumors. Enterome has entered clinical development stage, with EB8018 being currently evaluated in Crohn’s patients and E02401 will be tested in cancer patients
Robert Langer, the legendary MIT chemical engineer behind countless biotech startups, sits down with Amy Schulman, who is CEO of a company they co-founded called Lyndra. They will chat about how to turn ideas into innovations that make a difference.
Connect with thousands of like-minded attendees, speakers, sponsors and exhibitors during the grand opening of our exhibit hall. Enjoy a decadent display of hors d'oeuvres and grab a glass of wine/beer as our exhibitors showcase today's latest technologies in bioprocessing.